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Background: Systemic mast cell activation disease (MCAD) is characterized by an enhanced release of mast
cell-derived mediators, including eicosanoids, which induce a broad spectrum of clinical symptoms. Accordingly,
the diagnostic algorithm of MCAD presupposes the proof of increased mast cell mediator release, but only a few
mediators are currently established as routine laboratory parameters. We thus initiated an explorative study to
evaluate in vitro typing of individual eicosanoid pattern of peripheral blood leukocytes (PBLs) as a new diagnostic
tool in MCAD.
Methods: Using the “functional eicosanoid testing and typing” (FET) assay, we investigated the balance (i.e. the
complex pattern of formation, release and mutual interaction) of prostaglandin E2 (PGE2) and peptido-leukotrienes
(pLT) release from PBLs of 22 MCAD patients and 20 healthy individuals. FET algorithms thereby consider both basal
and arachidonic acid (AA)-, acetylsalicylic acid (ASA)-, and substance P (SP)-triggered release of PGE2 and pLT. The
FET assay was further supplemented by analyzing prostaglandin D2 (PGD2), as mast cell-specific eicosanoid.
Results: We observed marked PGE2-pLT imbalances for PBLs of MCAD patients, as indicated by a markedly
enhanced mean FET value of 1.75 ± 0.356 (range: 1.14–2.36), compared to 0.53 ± 0.119 (range: 0.36-0.75) for healthy
individuals. In addition, mean PGD2 release from PBLs of MCAD patients was significantly, 6.6-fold higher than from
PBLs of healthy individuals (946 ± 302.2 pg/ml versus 142 ± 47.8 pg/ml; P < 0.001). In contrast to healthy individuals,
PGD2 release from PBLs of MCAD patients was markedly triggered by SP (mean: 1896 ± 389.7 pg/ml; P < 0.001),
whereas AA and ASA caused individually varying effects on both PGD2 and pLT release.
Conclusions: The new in-vitro FET assay, supplemented with analysis of PGD2, demonstrated that the individual
patterns of eicosanoid release from PBLs can unambiguously distinguish MCAD patients from healthy individuals.
Notably, in our analyses, the FET value and both basal and triggered PGD2 levels were not significantly affected by
MCAD-specific medication. Thus, this approach may serve as an in-vitro diagnostic tool to estimate mast cell activity
and to support individualized therapeutic decision processes for patients suffering from MCAD.
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Hintergrund: Die systemische Mastzellaktivierungserkrankung (MCAD) ist durch eine vermehrte Freisetzung von
Mastzellmediatoren gekennzeichnet, die für ein sehr breites Spektrum an klinischen Symptomen in MCAD Patienten
verantwortlich sind. Das diagnostische Vorgehen bei MCAD erfordert den Nachweis einer erhöhten
Mediatorfreisetzung, wobei aber bisher nur eine begrenzte Anzahl an Mediatoren als Routinelaborparameter
etabliert ist. Es wurde daher eine Machbarkeitsuntersuchung initiiert, um die in vitro Bestimmung patientenspezifischer
Eicosanoidmuster an peripheren Blutleukozyten als neue diagnostische Möglichkeit bei MCAD zu evaluieren.
Methode: Analysiert wurde das Gleichgewicht der Freisetzung zwischen Prostaglandin E2 (PGE2) und
Peptidleukotrienen (pLT) aus peripheren Blutleukozyten von 22 MCAD Patienten und 20 gesunden Personen als
Kontrollen. Hierzu wurde die etablierte Methode der “funktionellen Eicosanoidtestung und -typisierung” (FET)
eingesetzt, deren Auswertealgorithmus sowohl die basale als auch die Arachidonsäure (AA)-, Acetylsalicylsäure
(ASA)- und Substanz P (SP)-stimulierte Freisetzung von PGE2 und pLT berücksichtigt. Zusätzlich wurde die
Freisetzung von Prostaglandin D2 (PGD2) analysiert, da PGD2 als ein für Mastzellen relativ spezifisches Eicosanoid
angesehen wird.
Ergebnisse: Verglichen mit der Kontrollgruppe (mittlerer FET Wert: 0.53 ± 0.119; Spannweite: 0.36-0.75) wurden für
MCAD Patienten deutliche PGE2-pLT Ungleichgewichte detektiert (mittlerer FET Wert: 1.75 ± 0.356; Spannweite:
1.14–2.36), wobei ein höherer FET Wert ein größeres Ungleichgewicht anzeigt. Zusätzlich war die mittlere PGD2
Freisetzung aus PBLs von MCAD Patienten signifikant 6.6-fach höher als in der Kontrollgruppe (946 ± 302.2 pg/ml
versus 142 ± 47.8 pg/ml; P < 0.001). Im Gegensatz zur Kontrollgruppe war die PGD2 Freisetzung bei MCAD Patienten
signifikant durch SP stimulierbar (Mittelwert: 1896 ± 389.7 pg/ml; P < 0.001), wohingegen AA und ASA sehr individuell
variierende Effekte auf die PGD2 und pLT Freisetzung induzierten.
Schlussfolgerungen: Der durch PGD2 ergänzte in-vitro FET Test war in der Lage, MCAD Patienten aufgrund der
individuellen Eicosanoid-Freisetzungsmuster ihrer PBLs eindeutig von gesunden Kontrollpersonen zu unterscheiden.
Die Aussagekraft der FET Werte wurden dabei nicht signifikant durch die MCAD-spezifische Medikation beeinflusst.
Der erweiterte FET Test könnte somit als diagnostische in-vitro Methode zur Abschätzung der Mastzellaktivität in
MCAD Patienten eingesetzt werden und für den individuellen Patienten zur Therapieoptimierung beitragen.Background
The term “systemic mast cell activation disease” (MCAD)
comprises disorders characterized by enhanced release of
mediators from mast cells. To date, three classes of sys-
temic MCAD have been classified, namely: systemic masto-
cytosis (SM), idiopathic mast cell activation syndrome
(MCAS), and mast cell leukemia (MCL) [1-3]. SM is char-
acterized by specific pathological mutations in exon 17 of
the tyrosine kinase KIT (mainly KITD816V) and mutation-
dependent histological and immunohistochemical findings,
as described in the World Health Organization (WHO)
criteria for diagnosis of SM [4]. MCAS is diagnosed in
patients presenting multiple symptoms, linked to mast
cell-derived mediators, who do not fulfil the WHO cri-
teria of SM [1-3,5-8]. MCL depicts an aggressive mast cell
neoplasm, which is defined by an increased number of
mast cells in bone marrow smears (≥20%) as well as nu-
merous circulating mature mast cells in the peripheral
blood (reviewed in [4]). Since MCL is extremely rare, this
MCAD class was not included in the present explorative
study.
Owing to known increased activity of mast cells in
MCAD patients, detection of enhanced mediator release
is part of the diagnostic algorithm of MCAD [1,2]. Thereare more than 200 different mediators which have been
identified to be released by mast cells. However, only a
few are being used as routine laboratory parameters in
diagnosing MCAD, which include tryptase, histamine,
and heparin (see e.g. Table 1 for levels of tryptase in the
MCAD patients included in the present study). The pat-
tern and extent of released mediators vary markedly in
patients with MCAD, depending on several factors such
as number and combination of mutated genes, the loca-
tion of the activated mast cells in the body, and the type
of trigger. Therefore, there is a need in additional, reli-
able, and meaningful biomarkers with less variability in
diagnosing MCAD.
Activated mast cells, amongst other mediators, rapidly
generate eicosanoids such as prostaglandin D2 (PGD2),
prostaglandin E2 (PGE2), and peptido-leukotrienes (pLTs)
[9,10], which have been suggested to represent biomarkers
of mast cell activation [11,12]. Determination of eicosanoid
levels may thus represent a promising tool in diagnosing
MCAD. However, quantification of these eicosanoids in
serum or urine of MCAD patients is hampered by in-
determinable and unpredictable individual factors which
strongly influence their formation, release, spillover into
blood or urine, and their degradation. These confounding
Table 1 Characteristics of MCAD patients
MCAS SM
No. Sex Age Tryptase* [μg/L] KIT Medication No. Sex Age Tryptase [μg/L] KIT Medication
1 f 30 2.0 neg. no 1 f 39 4.6 pos. yes
2 f 36 3.3 neg. no 2 f 44 3.3 pos. yes
3 f 36 9.4 neg. no 3 f 46 10.5 pos. yes
4 f 45 3.4 neg. no 4 f 53 27.0 pos. yes
5 f 46 11.3 neg. yes 5 f 55 4.9 pos. yes
6 f 46 3.0 neg. no 6 f 70 >200 pos. yes
7 f 57 3.9 neg. yes 7 m 44 24.7 pos. yes
8 f 59 4.4 neg. yes 8 m 51 >25 pos. yes
9 f 61 3.6 neg. no 9 m 52 40.7 pos. yes
10 f 71 5.7 neg. no 10 m 69 10.1 pos. yes
11 m 20 8.1 neg. no
12 m 38 n.d. neg. no
Mean 45.4 Mean 52.3
Median 45.5 Median 51.5
Range [20–71] [2.0-11.3] Range [39–70] [3.3- > 200]
f: female; m: male; n.d.: not determined; neg.: KITD816V negative; pos.: KITD816V positive; no: no MCAD-specific medication; yes: MCAD-specific medication (for details
see Additional file 1); *ImmunoCAP® Tryptase assay, normal range: < 11.4 μg/L.
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urine might be substantially reduced by applying a test,
originally introduced as “functional eicosanoid testing and
typing” (FET) in the diagnosis of aspirin-exacerbated re-
spiratory disease (AERD) by Schäfer and colleagues [13].
The FET analysis detects and quantifies the interactions of
both basal and triggered PGE2 and pLT release from pe-
ripheral blood leukocytes (PBLs) in vitro upon exposure
to arachidonic acid (AA), acetylsalicylic acid (ASA), or sub-
stance P (SP). The measured eicosanoid levels are then
processed by mathematical algorithms, which take into ac-
count known biochemical interactions of individual eicosa-
noids. The resulting FET value is therefore able to indicate
and classify changes in eicosanoid balance (i.e. the complex
pattern of formation, release and mutual interaction),
reflecting some of the pathophysiologic mechanisms of the
underlying diseases. In the clinical setting the standard FET
was already successfully applied for detection, prognosis,
and follow-up upon surgical/medical treatment of patients
suffering from diseases like intrinsic asthma, nonsteroidal-
anti-inflammatory (NSAID)-triggered hypersensitivity with
and without nasal polyps and/or asthma, urticaria, inflam-
matory bowel disease (e.g. ulcerative colitis, Crohn’s dis-
ease), gastrointestinal cancer, as well as sepsis and systemic
inflammatory response syndrome (for details, see [13] and
further references therein).
Here we report the results of a promising explorative,
diagnostic study, initiated to test the usefulness of FET
analysis in diagnosing MCAD. Therefore, PBLs were
collected from 22 MCAD patients and 20 healthy in-
dividuals and were analyzed by standard FET to try todistinguish patients with MCAD from healthy individuals.
Additionally, basal, AA-, ASA-, and SP-triggered release
of PGD2 from PBLs was included to potentially in-
crease specificity, suitability, and relevance of FET ana-
lysis with respect to determination of mast cell activity in
MCAD patients.
Patients and methods
Study population
Twenty-two Caucasian individuals, consecutively presenting
with MCAD (12 with diagnosis of MCAS and 10 with diag-
nosis of SM, according to WHO criteria) from February to
July 2012 at the St. Franziskus Hospital, Eitorf (Germany)
or the Department of Oncology, Haematology and Pallia-
tive Care, District Hospital of Waldbröl (Germany), were
randomly enrolled in the present prospective explora-
tive study to better reflect disease diversity (for patients’
characteristics, see Table 1 and Additional file 1). The
MCAD patients were clinically diagnosed according to
the current criteria for MCAD [1-4]. Diagnostic criteria
of SM and MCAS as well as the respective diagnostic
findings of the individual patients are depicted in
Additional file 2. The age of the patients ranged from 20
to 71 years (mean: 48.5 years; male to female ratio: 6:16).
For comparison, twenty age-matched healthy individuals
from Medical Clinic III, Friedrich-Alexander-University
Erlangen-Nuremberg (Germany) were included (mean
age: 44.3 years; range: 20–60 years; male to female ratio:
10:10). An extensive medical history of all healthy individ-
uals was conducted. The presence of an dysfunctional
immune system, immune defects, auto-immune disease,
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tract, atopy/allergy, hypersensitivity to drugs, aero- or
food-allergens, food-additives, also exhaustive physical
stress, immunization or xeno-immunoglobulin trans-
fusion was ruled out. IgE-mediated allergy was ruled out
by negative prick and specific IgE testing. Finally, no in-
take of antihistamines, steroids, or regular drugs other
than oral contraceptives was accepted. To estimate the
influence of MCAD-specific medication on eicosanoid
patterns, subgroup analysis for MCAD patients without
medication (MCAD-M; mean age: 40.3) and MCAD pa-
tients with MCAD-specific medication (MCAD+M; mean
age: 52.7 years) were performed. In particular the majority
of MCAS patients were devoid of MCAD-specific medica-
tion at the time of FET analysis, because they were in-
cluded into the study shortly after making the
diagnosis, but before starting MCAD-specific drug
therapy. For diagnostic purposes, typical mast cell mediator-
related symptoms were recorded by a standardized, vali-
dated questionnaire [14-16] (see also Additional file 1).
Data on basal tryptase level, as analyzed by the “Immuno-
CAP® Tryptase” standard assay for quantification of tryp-
tase in serum (Phadia GmbH, Freiburg, Germany; normal
range < 11.4 μg/L) and KITD816V mutation status, deter-
mined by polymerase chain reaction based methods, were
available for the included MCAD patients (see Table 1).
For differential diagnosis, other conditions that could also
be responsible for one or more of the reported symptoms
were ruled out by unchanged relevant pathognomonic la-
boratory parameters, imaging techniques, and/or endo-
scopic methods. Before participating in the present study,
all participants gave written informed consent to analysis
of their data for scientific purposes and were free to with-
draw from the study at any time. Blood samples were col-
lected by standard routine diagnostic methods without
further interventions. Therefore, a special ethical approval
was not mandatory for the MCAD patients. Blood collec-
tion from healthy individuals, in general, was approved by
the local ethical committee of the Friedrich-Alexander-
University Erlangen-Nuremberg (Germany). The present
study was performed in accordance with the ethical stan-
dards of the Helsinki Declaration 1975 (revised 2004).
FET analysis and quantification of eicosanoids
Peripheral venous blood was collected from patients and
healthy individuals and processed as described elsewhere
[17-19]. Briefly, 4.5 ml of heparinized blood were used
for isolation of PBLs. PBLs were resuspended in RPMI-
1640 cell culture medium without fetal calf serum and
adjusted to a cell density of 1 × 106 cells/ml. PBLs were
subsequently exposed to triggering factors, i.e. AA (10−5 M),
ASA (10−8 M), SP (10−12 M), or diluent for 20 min. In-
vitro formation and release of eicosanoids were stopped
by freezing at -80 °C. Samples were then stored for up tofour weeks at −80 °C before quantification of eicosanoids.
After thawing and centrifugation, eicosanoids were quan-
titatively analyzed in the cell supernatants by specific en-
zyme immunoassays (EIA) using highly sensitive and
specific competitive EIAs for PGE2, pLT (SIAT, Bad Essen,
Germany), and PGD2 (Cayman, Ann Abor, USA) accord-
ing to manufacturers’ protocols. Intra- and inter-assay var-
iances for the PGE2, PGD2, and pLT EIA were 7.4% and
8.6%, < 20% and < 20.6%, and 5.6% and 8.1%, respectively.
Recovery rate for PGE2, PGD2, and pLT was ≥ 95%; sensi-
tivities of the EIAs were 3.0, 19.5, and 1.0 pg/ml, respect-
ively ([20]; Cayman, Ann Abor, USA; [21]). The FET
validation process demonstrated no interference of the
test with ingestion of leukotriene receptor antagonists
prior to blood sampling. The personnel performing the ei-
cosanoid analyses were blinded to the source of the speci-
men (patient, healthy subject).
Calculation of the FET value
The FET value represents the integrating endpoint of the
standard FET assay. It considers both the metabolic net-
work of the cyclooxygenase and 5-lipoxygenase pathways
and summarizes the individual’s metabolic activities of
triggered and un-triggered PBLs [13,19,22]. For calcula-
tion of the FET value, the raw data of released PGE2 and
pLTs (analyzed in pg/ml) were processed according to a
specific mathematical algorithm [19]. This is achieved by
using both basal and triggered PGE2 and pLT levels,
which are then integrated according to their biochemical
interactions. The FET value is finally normalized, result-
ing in dimensionless categories between 0.0 and 3.0,
which reflect the balance/imbalance (i.e. the complex
pattern of formation, release and mutual interaction) of
in-vitro PBL-derived PGE2 and pLT and thus constitute
the patients’ individual eicosanoid pattern. Higher values
are indicative of disturbance of the physiologic PGE2-pLT
balance. Reliability of the calculated FET values was clini-
cally confirmed for patients suffering e.g. from aspirin in-
duced asthma and aspirin tolerant asthma (17, 22), gastric
ulcer, intestinal cancer (23), NSAID-triggered hypersensi-
tivity (18, 19), and urticaria (24).
Calculation of supplemental PGD2 ratios
The supplemental PGD2 ratios RA3, RS3, and RP3 were
calculated according to the following equations E1, E2,
and E3:
RA3 ¼ a3=b3; → i:e: AA‐triggered ratioð Þ ðE1Þ
RS3 ¼ s3=b3; → i:e: ASA‐triggered ratioð Þ ðE2Þ
RP3 ¼ p3=b3; → i:e: SP‐triggered ratioð Þ ðE3Þ
with:
a3: AA-triggered release of PGD2 [pg/ml];
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s3: ASA-triggered release of PGD2 [pg/ml];
p3: SP-triggered release of PGD2 [pg/ml].
Statistical methods
All data were tested for normal distribution using the
Kolmogorov-Smirnov test with Lilliefors correction. If
the assumption of normally distributed data could not
be rejected, arithmetic group means ± standard devia-
tions were calculated. The Student’s t-test for unpaired
values was used for group comparisons. If the normality
test failed in at least one of the study groups compared, all
data were expressed as group medians with data ranges
given in parentheses and comparison was calculated using
the Mann–Whitney U test. P values were considered sta-
tistically significant, if P ≤ 0.05. These statistical analyses
were performed using the SigmaPlot software (version
12.0, Systat Software GmbH, Erkrath, Germany). Optimal
cut-off levels and misclassification rates were calculated
by the method of ROC analysis, whereby the optimal cut-
off point is derived by maximizing the Youden index [23].
Respective calculations were performed with the BIAS
software for Windows (version 10.04; © 1989–2013 epsi-
lon Verlag; http://www.bias-online.de).
Results
Clinical presentation of the MCAD patients
All patients demonstrated, to a varying degree, intermit-
tently or chronically, a pattern of characteristic mast cell
mediator-related symptoms (see Additional file 1) which
was similar in patients with SM and MCAS. All SM
patients were KITD816V-positive and all MCAS patients
were KITD816V-negative. Five of 10 SM patients had tryp-
tase blood levels > 20 μg/L, defined as the cut-off level in
the corresponding WHO criteria. The remaining five SM
patients and all MCAS patients exhibited normal basal
tryptase levels (Table 1 and Additional files 1 and 2).
Medication of the MCAD patients
All 10 patients with SM were on treatment with mast
cell activity-reducing drugs (i.e. H1- and H2-antihista-
mines and cromoglicic acid) to alleviate symptoms in-
duced by the various mast cell mediators, in particular
by histamine (Table 1 and Additional file 1). Among the
12 patients with MCAS, only three were on medication
with antihistamines, whereas eight did not take any
medication, because they were enrolled in the study after
making the diagnosis, but before starting symptomatic
therapy. Two patients (one with MCAS, one with SM)
ingested NSAIDs, another two patients with SM were
treated with glucocorticoids, and three SM patients took
the leukotriene receptor antagonist montelukast at the
time of blood sampling. Nine of 22 patients (40.9%) did
not receive any MCAD-specific medication (MCAD-M)at the time of blood sampling, whereas 13 of 22 patients
(59.1%) were treated with MCAD-specific medication
(MCAD+M). MCAD-specific as well as other regular
medications of the enrolled MCAD patients varied highly,
depending on the individual symptom constellation, intol-
erances, and overlapping pathologies.
FET value
The mean FET value (1.75 ± 0.356) of MCAD patients was
significantly (P < 0.001) elevated, as compared to the healthy
individuals (0.53 ± 0.119) (Figure 1). Hence, standard FET
analysis distinguished MCAD patients from healthy indi-
viduals with a distinct cut-off FET value of 0.945 with
0.0% misclassification. A maximum FET value of 2.36 was
detected for MCAS patient #7 and SM patient #1, whereas
a minimum FET value of 1.14 was found for MCAS pa-
tient #5. SM patients exhibited a slightly higher mean FET
value (1.87 ± 0.284) than MCAS patients (1.65 ± 0.389),
but the difference did not reach statistical significance
(P = 0.155; Figure 1A). This was similar for the mean FET
value of MCAD patients without (MCAD-M: 1.67 ± 0.299)
and with MCAD-specific drug treatment (MCAD+M:
1.80 ± 0.393; P = 0.43), indicating that the standard
FET value, in the present explorative study, was suit-
able to distinguish MCAD patients from healthy individ-
uals, even when patients were already treated with
MCAD-specific drugs or NSAID (Figure 1B). To get an
impression concerning robustness of the FET test and the
FET algorithms with respect to NSAID intake raw data of
MCAS patient #8, who ingested ASA prior to blood
sampling, and SM patient #8, who indicated use of ibu-
profen, were modeled with subsequent calculation of the
FET value under the assumption that the NSAID medica-
tion led to inhibition of cyclooxygenase activity and thus
underestimated prostaglandin values and, in addition,
increase in 5-lipoxygenase activity with subsequent
overestimation of pLT. However, even at the assump-
tion of an unrealistically high under- (PGE2) and overesti-
mation (pLT) of 50% none of the two patients would
have been misdiagnosed by using the FET algorithms
(see Additional file 3).
Basal release of PGD2, PGE2, and pLT
We further analyzed the release of PGD2, because PGD2
represents a prominent mast cell eicosanoid, which is re-
lated to enhanced mast cell activity [10,11]. We thus hy-
pothesized that integration of PGD2 into the FET analysis
might reveal more MCAD-specific individual eicosanoid
patterns. Mean basal release of PGD2 from PBLs was in-
deed markedly enhanced (6.6-fold) in patients with MCAD
(946 ± 302.2 pg/ml; P < 0.001), as compared to healthy in-
dividuals (142 ± 47.8 pg/ml) (Figure 2A). A distinct cut-off
value of 333.31 pg/ml was calculated, however, with a mis-
classification rate of 2.3%. PGD2 release from PBLs of
Figure 1 FET values for patients suffering from MCAD. Data
represent the individual FET values of MCAD patients, derived group
means (black horizontal lines), and the optimal cut-off value (red
horizontal line) of 0.945 with 0.0% misclassification. Data were statistically
analyzed using the Student’s t-test for unpaired values and ROC analysis,
respectively. Control: healthy individuals (n = 20), MCAD: patients
with mast cell activation disease (n = 22); (A) MCAS: MCAD patients
with mast cell activation syndrome (n = 12); SM: MCAD patients with
systemic mastocytosis (n = 10); (B) MCAD-M: MCAD patients without
MCAD-specific medication (n = 9); MCAD+M: MCAD patients with
MCAD-specific medication (n = 13).
Figure 2 Basal release of PGD2 from PBLs of MCAD patients.
Data represent individual PGD2 levels of MCAD patients and healthy
controls, derived group means (black horizontal lines), and the
optimal cut-off value (red horizontal line) of 333.31 pg/ml with 2.3%
misclassification. Data were statistically analyzed using the Student’s
t-test for unpaired values and ROC analysis, respectively. Control:
healthy individuals (n = 20), MCAD: patients with mast cell activation
disease (n = 22); (A) MCAS: MCAD patients with mast cell activation
syndrome (n = 12); SM: MCAD patients with systemic mastocytosis
(n = 10); (B) MCAD-M: MCAD patients without MCAD-specific
medication (n = 9); MCAD +M: MCAD patients with MCAD-specific
medication (n = 13).
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than that from PBLs of SM patients (mean: 829 ± 298.0 pg/
ml), but the difference did not reach statistical significance
(P = 0.096) (Figure 2A). Maximum basal PGD2 level of
1574 pg/ml was observed for MCAS patient #5 whereas
the lowest PGD2 level was observed for SM patient #1.
MCAD-M and MCAD+M patients (mean: 964 ± 250.4 pg/
ml and 934 ± 343.0 pg/ml, respectively) had similar mean
basal PGD2 levels (Figure 2B), with a broader variance in
the MCAD+M subgroup.
Mean basal release of PGE2 and pLT from PBLs of
MCAD patients was significantly higher (1.8-fold, P =
0.005, and 3.2-fold, P < 0.001, respectively), than that
of healthy controls (Additional file 4). However, basal
PGE2 and pLT levels were less discriminative than theFET value (which considers both basal and triggered
PGE2 and pLT levels and their biochemical interac-
tions) or the basal PGD2 release concerning the dis-
crimination of patients from healthy controls. ROC
analysis indicated misclassification rates of 27.0% and
11.4% for basal PGE2 and pLT, respectively, when cal-
culating the respective optimal cut-off levels of
207.65 pg/ml (PGE2) and 140.55 pg/ml (pLT). Notably,
PBLs from MCAS patients released significantly more
PGE2 (median: 228 pg/ml; range: 108–994 pg/ml; P =
0.018) than PBLs from SM patients (median: 136;
range: 40–629 pg/ml) (Additional file 4). Mean basal
PGE2 as well as pLT release was not significantly dif-
ferent in patients without and with MCAD-specific
medication (data not shown).
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MCAD-patients, we expanded PGD2 analysis by investi-
gating AA-, ASA-, and SP-triggered release of PGD2,
since these triggering factors are routinely used in
standard FET analysis and are of relevance in MCAD.
AA-triggered PGD2 release
AA, the physiological substrate of both the cyclooxygen-
ase and 5-lipoxygenase pathways, seemed to be less active
in stimulating PGD2 release from PBLs of MCAD patients
than of healthy individuals, when expressed as PGD2 ratio
(i.e. PGD2 level after AA stimulation divided by basal
PGD2 release; Table 2): Median AA-triggered PGD2 ratio
was significantly lower for MCAD patients (1.13; range:
0.20-3.26; including six non- or adverse-responder; P =
0.007) than for healthy controls (1.43; range: 0.88-2.46;
one non-responder). There was no significant difference
(P = 0.100) between MCAS (1.15; range: 0.63-1.63) and SM
patients (1.07; range: 0.20-3.26); the drug treatment sub-
groups MCAD-M (1.17; range: 0.64-1.63) and MCAD+M
(1.11; range: 0.20-3.26) also had similar median PGD2
ratios after AA stimulation (Table 2).
The observed lower median AA-triggered PGD2 ratio
for MCAD patients was perhaps a result of the signifi-
cantly higher basal PGD2 levels in this group, as in par-
ticular PBLs from some MCAD patients with basal PGD2
levels > 1000 pg/ml did not respond with enhanced,
but with reduced release of PGD2 upon AA-triggering
(Figure 2, Additional file 5). We thus hypothesized that
high basal PGD2 release might limit further physiological
AA-triggering. Nevertheless, median AA-triggered PGD2
level for MCAD patients were significantly higher
(median: 964 pg/ml; P < 0.001) than for healthy controls
(median: 180 pg/ml; range: 144–473 pg/ml), however with
high variance (range: 236–1818 pg/ml). Because of the in
part opposite effects of AA on PBLs from MCAD patients
and the high range of dispersion of the AA-triggered
PGD2 values, AA-triggered PGD2 release seemed not toTable 2 PGD2 ratios
Trigger Control MCAD MCAS
Median ratio
(range)
Median ratio
(range)
Median rat
(range)
AA 1.43 1.13** 1.15**
(0.88-2.46) (0.20-3.26) (0.63-1.63)
ASA 1.10 1.10 1.16
(0.93-1.45) (0.21-3.30) (0.57-2.65)
SP 0.88 2.05*** 1.71**
(0.40-1.34) (0.79-6.64) (0.79-4.87)
PGD2 ratio: PGD2 release from PBLs in the presence of a trigger, divided by basal PG
mast cell activation disease (n = 22); MCAS: MCAD patients with mast cell activation
MCAD-M: MCAD patients without MCAD-specific medication (n = 9); MCAD +M: MC
control: ***P < 0.001, **P < 0.01, *P < 0.05, Mann–Whitney U test.be a sufficiently decisive endpoint for diagnostically differ-
entiating MCAD patients from healthy controls.
ASA-triggered PGD2 release
PBLs were exposed to ASA, a known trigger in some but
not all MCAD patients. The median of the ASA-triggered
PGD2 ratios (i.e. PGD2 level after incubation with ASA
divided by basal PGD2 release) was not elevated in MCAD
patients, when compared with healthy individuals (1.10
and 1.10, respectively; P = 1.000), irrespective of MCAD
subclass or medication subgroup (for details see Table 2).
However, when evaluating the individual ASA-triggered
reactions on PGD2 release, highly variable effects were
observed, in terms of no effect (e.g. SM patient #2), eleva-
tion (e.g. 3.3-fold increase for SM patient #1), or reduc-
tion in PGD2 release (e.g. decrease to 21% of the basal
PGD2 level for SM patient #8). Variance of the ASA-
triggered PGD2 ratio was markedly higher in MCAD pa-
tients (range: 0.21-3.30) than in healthy controls (range:
0.93-1.45) (Table 2).
Since ASA can be used therapeutically to decrease
prostaglandin-related symptoms in MCAD patients [24,25],
but can also trigger anaphylactic reactions, it was of spe-
cial interest to look more closely into the individual ASA-
triggered reactions of PBLs from MCAD patients. We,
therefore, used vector plots to investigate individual ASA-
triggered dynamics of the PGD2-pLT eicosanoid pattern,
because both eicosanoids can account for profound ad-
verse reactions. These plots summarize and integrate
both basal (origin of arrows) and ASA-triggered PGD2
and pLT release (arrowhead) (Figures 3A and 3B). PBLs
from healthy individuals were characterized by no or only
marginal ASA-triggered modulation of the dynamics of
eicosanoid release. In contrast, PBLs from MCAD patients
demonstrated extended and highly individual responses
to ASA with all kinds of different PGD2-pLT dynamics.
PBLs from some patients reacted with a markedly in-
creased release, of mainly PGD2 (e.g. MCAS patients #1SM MCAD-M MCAD +M
io Median ratio
(range)
Median ratio
(range)
Median ratio
(range)
1.07 1.17* 1.11*
(0.20-3.26) (0.63-1.63) (0.20-3.26)
1.03 1.18 1.03
(0.21-3.30) (0.57-2.65) (0.21-3.30)
2.56*** 2.07*** 2.04***
(1.61-6.64) (0.99-4.87) (0.79-6.64)
D2 release. Control: healthy individuals (n = 10); MCAD: patients suffering from
syndrome (n = 12); SM: MCAD patients with systemic mastocytosis (n = 10);
AD patients with MCAD-specific medication (n = 13). Significantly different from
Figure 3 Vector plots of ASA-triggered PGD2 and pLT dynamics
derived from PBLs of MCAS and SM patients and healthy
controls. Origin of arrows: basal eicosanoid release; arrowheads:
ASA-triggered eicosanoid release; grey arrows: healthy individuals
(n = 20); black arrows: MCAD-M, MCAD patients without MCAD-specific
medication (n = 9); red arrows: MCAD + M, MCAD patients with
MCAD-specific medication (n = 12); black numbers: patients’ identification
numbers (see Table 1). (A) MCAS: MCAD patients with mast cell
activation syndrome (n = 12); (B) SM: MCAD patients with systemic
mastocytosis (n = 9). One SM patient was not depicted in the figure,
because of extraordinarily high pLT release, both basal and after ASA
exposure (basal PGD2 and pLT release: 531 and 258 pg/ml, respectively;
ASA-triggered PGD2 and pLT release: 2056 and 853 pg/ml, respectively).
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to be ASA intolerant) and patient #12; Figure 3A] and
some with an enhanced release of both PGD2 and pLT
(e.g. MCAS patient #8, Figure 3A, and SM patient #1,
not depicted in Figure 3B, because of extraordinarily high
pLT values). In other MCAD patients no or only minor
effects on the PGD2-pLT eicosanoid pattern [e.g. SM pa-
tients #2 (known to be ASA tolerant), and SM patient #5;
Figure 3B] were observed upon in-vitro exposure to ASA.
Furthermore, some patients demonstrated down regula-
tion of PGD2 and/or pLT release (e.g. MCAS patients #3
and #9, Figure 3A, and SM patient #6, Figure 3B), in part
with opposed effects on the other eicosanoid (e.g. SMpatients #8 and #10, Figure 3B). Taken together, the effects
of ASA on the PGD2-pLT dynamics in MCAD patients
thus strongly differed between individuals with regard to
the eicosanoid type/s involved as well as the extent and
direction of the effect. Susceptibility of MCAD patients to
ASA did not seem to be uniformly influenced by the indi-
vidual MCAD-directed medication, because comparably
treated patients did not demonstrate the same modulation
pattern (see Additional file 6).
SP-triggered PGD2 release
The neuropeptide SP was shown to be elevated in blood
of patients suffering from mastocytosis [26]. In our study,
SP caused a marked increase in PGD2 release from PBLs
of 19 of 22 MCAD patients (Table 2, Figures 4 and 5).
The SP-triggered PGD2 ratio (i.e. PGD2 level after SP
stimulation divided by basal PGD2 level) was significantly
higher in MCAD patients (median: 2.05; P < 0.001) than in
healthy controls (median: 0.88), with wide ranges for both
MCAD patients (0.79-6.64) and healthy controls (0.40-
1.34) (Table 2). This was observed irrespective of the
MCAD subclass or MCAD-specific drug treatment. The
SP-triggered PGD2 ratio was significantly higher for SM
patients (median: 2.56, range: 1.61-6.64; P = 0.044) than
for MCAS patients (median: 1.71; range: 0.79-4.87). The
medication subgroups demonstrated nearly identical SP-
triggered PGD2 ratios (MCAD-M: median: 2.07; range:
0.99-4.87; MCAD+M: median 2.04; range: 0.79-6.64),
however with a broader variance in MCAD-M patients.
The SP-triggered PGD2 ratio was maximal for SM pa-
tient #1 (6.64), followed by MCAS patient #11 (4.87),
and SM patient #3 (3.48). In 3 of 22 MCAD patients
(MCAS patients #5, #8, and #12) no increase or even
a slight decrease in SP-triggered PGD2-ratio of PBLs
occurred.
In view of the obviously strong effect of SP on PGD2 re-
lease from PBLs of MCAD patients and considering the
known biochemical interaction of the COX and 5-LOX
pathways, we further analyzed the effect of SP on both
PGD2 and pLT levels in more detail. Again, we used vector
plots to investigate individual SP-triggered dynamics of the
PGD2-pLT eicosanoid pattern. These plots summarize and
integrate both basal (origin of arrows) and SP-triggered
PGD2 and pLT release (arrowhead). PBLs from healthy
individuals were characterized by no or only marginal SP-
triggered modulation of the dynamics of eicosanoid release
(Figures 4A and 4B). In contrast, PBLs from 19 out of 22
MCAD patients demonstrated marked increase in SP-
triggered PGD2 release revealing a significantly (P <
0.001) enhanced mean PGD2 level of 1896 ± 389.7 pg/ml
(range: 939 to 2303 pg/ml), as compared to 130 ± 53.5 pg/
ml (range: 50–294 pg/ml) for healthy individuals (Figures 4
and 5). PBLs from SM patients exhibited significantly higher
SP-triggered PGD2 release (2079 ± 207.2 pg/ml; P = 0.0205;
Figure 4 Vector plots of SP-triggered PGD2 and pLT dynamics
derived from PBLs of MCAS and SM patients and healthy
controls. Origin of arrows: basal eicosanoid release; arrowheads:
SP-triggered eicosanoid release; grey arrows: control, healthy individuals
(n = 20); black arrows: MCAD-M, MCAD patients without MCAD-
specific medication (n = 9); red arrows: MCAD +M, MCAD patients
with MCAD-specific medication (n = 13); black numbers: patients’
identification numbers (see Table 1) (A) MCAS: MCAD patients with
mast cell activation syndrome (n = 12); (B) SM: MCAD patients with
systemic mastocytosis (n = 10).
Figure 5 SP-triggered release of PGD2 from PBLs of MCAD
patients. Data represent individual PGD2 levels of MCAD patients
and healthy controls, derived group means (black horizontal lines),
and the optimal cut-off value (red horizontal line) of 616.38 pg/ml
with 0.0% misclassification. Data were statistically analyzed using the
Student’s t-test for unpaired values and ROC analysis, respectively.
Control: healthy individuals (n = 20), MCAD: patients with mast cell
activation disease (n = 22); (A) MCAS: MCAD patients with mast cell
activation syndrome (n = 12); SM: MCAD patients with systemic
mastocytosis (n = 10); (B) MCAD-M: MCAD patients without
MCAD-specific medication (n = 9); MCAD + M: MCAD patients
with MCAD-specific medication (n = 13).
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446.0 pg/ml; Figure 5A). No significant difference was
noted between the two medication groups MCAD-M
and MCAD+M (1863 ± 376.8 and 1919 ± 411.9 pg/ml,
respectively; P = 0.373; Figure 5B). Notably, two of the SP
non-responders, concerning PGD2 release, instead showed
enhanced pLT release upon SP-stimulation. Analysis of the
vector plots demonstrated partially pronounced stimula-
tion of SP-triggered pLT release for 18 of 22 MCAD pa-
tients (Figure 4). Mean pLT release amounted to 393 ±
137.2 pg/ml (range: 188–687 pg/ml) for MCAD patients,
as compared to 72 ± 33.1 pg/ml (range: 23–131 pg/ml) for
healthy individuals (Additional file 7). MCAS patients
exhibited a higher mean pLT release of 433 ± 153.9 pg/ml
than SM patients (mean: 345 ± 101.4 pg/ml) upon SPstimulation, but the difference did not reach statistical sig-
nificance (P = 0.068; Additional file 7).
As depicted in Figures 4 and 5 and in Additional file 7,
there was no overlap of the individual SP-triggered PGD2
and pLT levels of MCAD patients with that of healthy indi-
viduals. Subsequently, distinct cut-off values of 616.38 pg/
ml and 159.59 pg/ml could be calculated for SP-triggered
PGD2 and SP-triggered pLT levels, respectively, with each
0.0% misclassification rate. Especially the SP-triggered
PGD2 level was highly decisive concerning distinction of
MCAD patients from healthy controls (Figure 5).
Discussion
MCAD is characterized by an enhanced release of mast
cell-derived mediators, which are linked to a broad spectrum
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MCAD patients are highly individual and can differ signifi-
cantly from patient to patient, depending, amongst others,
on the types and amounts of released mediators. Thus,
confirmation of increased mediator release is mandatory
in the diagnostic algorithm of MCAD [1,2]. Our present
explorative study therefore investigated the significance of
a PGD2-supplemented FET analysis with PBLs as a new
in-vitro diagnostic tool in MCAD.
The functional in-vitro method of FET (i.e. “functional
eicosanoid testing and typing”) was originally designed by
Schäfer and colleagues for diagnosing aspirin-exacerbated
respiratory disease (AERD; for review, see [13]). Ac-
cordingly, the standard version of FET analysis uses an
AERD-adapted panel of eicosanoids (i.e. PGE2 and pLT),
AERD-approved triggers (AA, ASA, SP), and also AERD-
adapted mathematical algorithms for calculation of the
FET value as the integrating test read out. The present
study now applied for the first time standard FET analysis
to evaluate PBL-derived eicosanoid patterns for MCAD
patients. Irrespective of the AERD-focused methodological
background of the FET approach, standard FET analysis
clearly differentiated MCAD patients (both MCAS and
SM patients) from healthy individuals, since markedly en-
hanced FET values were observed in the randomly re-
cruited patient group. Data thereby enabled calculation of
a distinctive cut-off value (i.e. 0.945) with a misclassifica-
tion rate of 0.0%, indicating clear cut-off differences in the
balance of PGE2 and pLT in MCAD patients and healthy
individuals. Therefore, the standard FET analysis, which re-
flects the complex interactions of PGE2 and pLT [18] could
be a useful in-vitro tool in distinguishing MCAD patients
from healthy individuals.
The striking PGE2 and pLT imbalances we found in
MCAD patients are in agreement with known rapid gen-
eration of both PGE2 and pLT by activated mast cells
[9,10,27,28]. However, increased FET values have also
been observed in other inflammatory diseases accompan-
ied by pathological eicosanoid patterns, such as urticaria
and asthma in patients suffering from NSAID-triggered
hypersensitivity, gastroduodenal ulcer, and gastrointestinal
cancer [13,29-33]. Those disorders are often found as
MCAD-dependent and -independent comorbidities. Thus,
standard FET analysis seems to lack MCAD specificity,
but in combination with additional clinical findings, la-
boratory parameters, and/or imaging techniques, indica-
tive for mast cell activation, it could be used to confirm
the diagnosis of MCAD, irrespective of the biologic het-
erogeneity of the MCAD patients.
To yield more MCAD-specific eicosanoid patterns and to
potentially enhance the power of FET analysis in diagnosing
MCAD, standard FET analysis was supplemented with ana-
lysis of PBL-derived PGD2. PGD2 is the major prostanoid
released by activated mast cells [34] and it was proposedto be an indicator of mast cell activity in vivo, because
mast cells are known to produce the most significant
quantities of PGD2 among leukocytes [11,12]. Further-
more, PGD2 is assumed to be involved in hemodynamic
symptoms of systemic mast cell diseases and in other
symptoms such as increased mucus secretion, broncho-
constriction, and pain [2,25,35,36].
In the present study, markedly higher basal release of
PGD2 from PBLs of MCAD patients than from healthy
controls was indeed demonstrated. This is in line with pre-
vious studies, which showed enhanced levels of the major
PGD2 metabolite PGD-M in plasma and urine of patients
with SM by modified mass-spectrometric methods [36-38].
Concerning cellular origin of PBL-derived PGD2, previous
reports indicated that PBLs comprise hematopoietic mast
cell-committed progenitor cells as well as small numbers
of mature mast cells [39,40] and, in addition, small num-
bers of mature mast cells have been detected in periph-
eral blood cells of patients with SM [41]. Furthermore,
CD34-KIT+ blood cells were detected that were identified
to represent circulating precursor cells of mast cells, and
their quantity was correlated with the severity of SM [42].
Therefore, markedly elevated PGD2 release from PBLs of
MCAD patients, as measured by the PGD2-supplemented
FET assay, might at least in part reflect mast cell activity,
and PBLs might serve as suitable specimens for analyzing
mast cell activity and individual eicosanoid release patterns
of MCAD patients. But, other cell types such as T helper 2
cells [43], eosinophils, and basophils, primed by or in close
cross-talk with activated mast cells could have also contrib-
uted to the high basal PGD2 release from PBLs of MCAD
patients. For example, untriggered human blood eosino-
phils constitutively express hematopoietic prostaglandin D
synthase and secrete PGD2 upon pre-incubation with AA
[44]. Furthermore, IgE-mediated PGD2 release was docu-
mented for human basophils [45]. Notably, MCAD can be
accompanied by eosinophilia and/or basophilia [46,47] and
4 of 22 MCAD patients in the present study showed eo-
sinophilia or both eosinophilia and basophilia (Additional
file 1). Thus, these cell types might also have contributed
to PBL-derived PGD2 release. However, it was beyond the
scope of our explorative study to evaluate in detail the cel-
lular origin of PGD2 in the investigated samples. This has
to be done in a respective future study.
Besides high PGD2 release, we also demonstrated en-
hanced mean basal release of PGE2 and pLT from PBLs
of MCAD patients, as compared to healthy controls.
This finding is in line with reports that mast cells are a
major source of cysteinyl LTs and that urinary excretion
of LTE4 is increased in patients suffering from SM
[48,49]. Accordingly, increased release of both PGE2 and
pLT may contribute to induction of various clinical symp-
toms in MCAD patients. Increased basal release of pLT
from PBLs has also been observed in patients suffering
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elevated basal release of pLT in patients with AERD was
shown to be due to increased activity of monocytes, granu-
locytes, and T-lymphocytes [17,19]. Similarly, detection of
an elevated release of pLT from PBLs of MCAD patients in
our study suggests that not only the activity of mast cells
but also the activity of other immune competent cells may
be increased in MCAD. This supports the idea that symp-
toms of MCAD, in particular in patients with high disease
intensity, could be the consequence of an amplified cas-
cade of basophilic, eosinophilic, or generalized leukocyte
activation with subsequent eicosanoid and cytokine release.
Induction of eicosanoid and cytokine release from these
cell types might thereby be triggered by liberation of cer-
tain mast cell-derived mediators [50] and pLTs are in turn
able to enhance degranulation of mast cells through para-
crine and autocrine mechanisms [51,52].
Quantification of basal release of PGD2, PGE2, and
pLT from PBLs of MCAD patients by FET analysis may
not only aid in indicating mast cell activity or leukocyte
activity in general, but might also support therapeutic
decision processes for individual treatment of MCAD
patients. In this respect, our results point to therapeutic
options in MCAD (in addition to antihistamines and
mast cell stabilizing drugs), such as the use of anti-LT
drugs (i.e. 5-lipoxygenase inhibitors or LT-receptor antag-
onists) in patients demonstrating high basal and/or trig-
gered pLT levels. Notably, the beneficial use of the
leukotriene receptor antagonist montelukast has already
been reported in the treatment of systemic and cutaneous
mastocytosis [53-55]. Besides its function as leukotriene
receptor antagonist montelukast was, in addition, shown
to exhibit some 5-LOX-inhibiting potential [56,57], which
might further aid in controlling pLT release in MCAD pa-
tients. In patients with high basal and/or triggered levels
of PGE2 and/or PGD2 in FET analysis prescription of cy-
clooxygenase inhibitors such as ASA or coxibs could in
turn be considered, as these patients might benefit from
COX-inhibition. Further studies are necessary to evalu-
ate whether the present in-vitro method is suited to sup-
port such therapeutic decision processes.
NSAIDs such as ASA, which can be beneficial for some
MCAD patients by reducing prostanoid-related symptoms
[24,25], can also be a strong trigger in some MCAD pa-
tients, causing sometimes life-threatening anaphylactic re-
actions [58]. Thus, prior knowledge of susceptibility of
MCAD patients to ASA is important. In the present study,
we observed highly variable effects of ASA on in vitro-
treated PBLs from MCAD patients in terms of no effect,
elevation, and reduction of PBL-derived PGD2 and pLT
release, with both same and opposing effects. This clearly
contrasts with the almost homogenous SP-triggered ef-
fects on PBLs from MCAD patients and may reflect the
highly individual susceptibility of MCAD patients to ASA.For instance, one patient with known ASA intolerance
exhibited significant induction of PGD2 and pLT release by
ASA, whereas another patient with known tolerance dem-
onstrated no effect of ASA on eicosanoid production. We
thus assume that the new functional in-vitro FET approach
has the potential to detect free of risk the individual predis-
position for adverse or tolerant reactions of MCAD patients
to diverse drug treatment. As, in the present study, suscep-
tibility of the individual patients to ASA (tolerance, intoler-
ance) was not recorded explicitly at the time of blood
sampling, supporting data are limited. Thus, to further
evaluate this assumption it needs future validation studies
with larger groups of MCAS and SM patients, appropriate
reference groups, and extended anamnestic endpoints.
As described above, FET analysis considers both basal
and triggered eicosanoid release from PBLs to receive
additional information on the dynamics of eicosanoid
release and on respective individual eicosanoid patterns.
Besides ASA, PBLs were also exposed to the neuropep-
tide SP. SP is a strong trigger for mast cells of different
origin [26,27,59] and is known to cause de-novo synthe-
sis of PGD2 and leukotrienes [60]. Notably, elevated
plasma levels of SP and other neuropeptides have been
detected in patients with SM, thereby correlating with
mast cell load [26] and urinary levels of SP were in-
creased in some patients with urticaria pigmentosa [61].
Thus, SP seems to be a relevant endogenous trigger of
mast cell activity in MCAD. In our explorative diagnos-
tic study, the release of PBL-derived PGD2 was mark-
edly elevated in 86% of the MCAD patients upon
in-vitro exposure of cells to SP. Such an effect was ab-
sent in the healthy control group. SP-triggered PGD2
release from PBLs alone or in combination with SP-
triggered pLT release offered the most decisive discrim-
ination of MCAD patients from healthy individuals, as
the SP-triggered PGD2 levels of all MCAD patients were
higher than that of the healthy individuals, with a dis-
tinct cut-off value for SP-triggered PGD2 of 616 pg/ml.
The finding that PBLs of healthy controls exhibited
nearly no SP-triggered effects in vitro, suggests that PBLs
of MCAD patients are more prone to SP stimulation. En-
hanced SP sensitivity has previously been demonstrated
for urticaria pigmentosa skin mast cells. SP challenge me-
diated higher spontaneous histamine release from urticar-
ial pigmentosa mast cells than from mast cells of healthy
skin [62]. Enhanced SP sensitivity may thereby be due
to increased expression of SP receptors on pathologic-
ally altered mast cells, as some mast cell cell lines were
shown to express SP receptors [63,64]. Additionally, van
der Kleij and co-workers [65] demonstrated induction of
neurokinin 1 receptor expression in normal bone marrow-
derived mast cells by interleukin 4 and the tyrosine kinase
KIT ligand stem cell factor, and thus KIT activation ap-
pears to make the cells more sensitive to SP [60,66]. Since
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stem cell factor independent KIT activity might also lead
to enhanced neurokinin 1 receptor expression with subse-
quently increased SP sensitivity. But, also neurokinin 1
receptor-independent SP-mediated mechanisms of mast
cell activation might occur [65]. Notably, at lower SP
levels, SP-triggered PGD2 and pLT release seemed to
take place in the absence of mast cell degranulation
[60]. Nevertheless, the mechanisms behind increased
SP-sensitivity of PBLs from MCAD patients remain to
be further elucidated.
The increased susceptibility of PBLs from MCAD to SP
and especially SM patients, as found in the present study,
together with the documented elevated blood levels of neu-
ropeptides in MCAD patients [24,61] may support the con-
cept of SP-mediated enhanced release of cytokines from
PBLs. These cytokines could in turn induce symptoms
by activating mast cells [67] and/or acting upon other ef-
fector cells. Thus, to reduce mast cell activity and MCAD-
associated increased PBL activity neuropeptide receptor
antagonists, acting on the neurokinin-1 receptor for SP or
on the Mas-related gene receptor X2, as a common receptor
for SP, somatostatin, and VIP [65,68], might be additional
promising treatment options in the therapy of MCAD.
The PGD2-supplemented FET approach constitutes a
remarkable improvement in determining increased medi-
ator release in MCAD patients, compared to e.g. PGD-M
quantification in plasma and urine by mass-spectrometric
methods or quantification of serum tryptase levels. First of
all, the new functional diagnostic test offers evaluation of
individual eicosanoid patterns. It thereby integrates mul-
tiple mediators, known mediator interactions, and also
basal and triggered eicosanoid dynamics. As a functional
ex-vivo approach, this assay is less susceptible to unpre-
dictable individual factors influencing formation, release,
and spill over into blood or urine of mediators, or their
degradation. Interestingly, determination of both basal
mediator release and mediator levels during or shortly
after a triggering “event” with assumed mast cell activation
has recently been proposed as one criterion for diagnosing
MCAS [2,8]. But, this does not seem easy to perform
in vivo, because of the unpredictability of “events” and the
in part unstable mediators or metabolites. In this context,
the “event”-independent PGD2-supplemented FET might
be a very useful tool, because it can simulate “events”
ex vivo with isolated PBLs of MCAD patients. Finally, in
contrast to e.g. mass-spectrometric methods, the pre-
sented FET approach for diagnosing MCAD is easier to
perform, more affordable, and suitable for widespread use
in clinical laboratories.
Conclusions
Taken together, we demonstrate that the PGD2-supple-
mented FET assay represents a suitable in-vitro tool inthe diagnostics of MCAD and for monitoring leukocyte
and more generally disease activity. The standard FET
value can unambiguously differentiate MCAD patients
from healthy individuals, irrespective of patients’ individ-
ual medication or MCAD subclass. Our findings also
show that PGD2 analysis may provide some specificity to
FET analysis for its use in the diagnostic process of
MCAD. However, for a more important and decisive role
of the test in the diagnostic work-up of MCAD, the ability
of the PGD2-supplemented FET to discriminate MCAD
patients from patients with immunological/allergic and/
or other inflammatory diseases will have to be evaluated
in well-designed future studies. In particular, SP-triggered
release of PGD2 and pLT from PBLs seems to be promis-
ing estimators of metabolic hyperactivity of PBLs from
MCAD patients and may aid in distinguishing MCAD
patients from healthy subjects and perhaps other dis-
eases. Additionally, FET data may provide some predictive
hints whether cyclooxygenase inhibitors or receptor an-
tagonists are appropriate options for the individual pa-
tient. The PGD2-supplemented FET assay may serve as a
new cost-effective and robust diagnostic in-vitro tool in
diagnosing and monitoring MCAD and deserves further
evaluation and validation with development of MCAD-
specific algorithms.Additional files
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